Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 681.79% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Dec 2025, up 681.79%, and an annual FY2025 reading of $4.8 million, up 681.79% over the prior year.
  • Other Non-Current Liabilities was $4.8 million for Q4 2025 at Heron Therapeutics, up from $4.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q4 2025 and bottomed at $241000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 4 years is $887312.5, with a median of $241000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities changed 0.0% in 2023, then soared 1847.72% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $241000.0 in 2022, then changed by 0.0% to $241000.0 in 2023, then soared by 155.19% to $615000.0 in 2024, then soared by 681.79% to $4.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for HRTX at $4.8 million in Q4 2025, $4.7 million in Q3 2025, and $747000.0 in Q2 2025.